Every Form 4 that Amgen Inc (AMGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AMGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMGN filings page.
Amgen Inc. senior vice president of business development Rachna Khosla reported a set of option-related and open-market transactions. On 2026-08-13 she exercised 1,252 options at $162.60 per share to acquire 1,252 common shares, then sold those 1,252 shares at an average price of $416.4256, including shares sold to cover the option exercise price and required withholding taxes. She also sold 2,000 common shares on 2026-08-11 at an average price of $412.567 per share.
Busch Matthew C. reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. reported that officer Matthew C. Busch, VP, Finance & CAO, received an equity compensation award of 730 shares of Common Stock in the form of Restricted Stock Units (RSUs) on 2026-08-07. The RSUs were granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vest in four equal annual installments of 25%, beginning on 8/7/2027. Vested RSUs will be settled in shares of Amgen common stock on a one-to-one basis. Following this award, Busch holds 5,080 shares directly, which include 45 Dividend Equivalents (DEs) credited to his unvested RSUs.
Amgen Inc. director Omar Ishrak reported an acquisition of 85.1685 shares of Amgen common stock on 2026-08-07 as a grant or award, at a stated price of $0.0000 per share. Following this award, he holds 7,485.9046 shares directly. A related footnote states that these holdings include 460 Dividend Equivalents (DEs) credited to unvested Restricted Stock Units under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan, which are paid out in common shares on a one-to-one basis according to the RSU vesting schedule, with any remaining fractional share settled in cash.
AMGEN INC director Charles M. Holley reported a compensation-related acquisition of 103.4189 shares of common stock on 2026-08-07, recorded at a price of $0.0000 per share. Following this grant, he holds 12,990.4520 shares directly, which include 1,652 Dividend Equivalents credited to unvested Restricted Stock Units under Amgen’s equity incentive plan. He also reports 1,260.0000 shares held indirectly through the Holley Family Trust.
Drake Michael V reported acquisition or exercise transactions in this Form 4 filing.
AMGEN INC director Michael V. Drake reported an automatic grant/award of 63.8764 shares of common stock on 2026-08-07, at a stated price of $0.0000 per share as compensation. Following this award, his directly held position is 5,876.1633 shares, including 377 Dividend Equivalents linked to unvested Restricted Stock Units that pay out in common stock on a one-to-one basis as they vest.
Amgen Inc. executive Derek Miller, SVP of Human Resources, exercised stock options for a total of 3,890 shares of common stock on August 6, 2026, at strike prices of $162.60 and $177.46 per share. He then sold 3,890 common shares at a weighted-average price of $402.5444 per share in open market or private transactions. Footnotes state these sales include shares used to cover the option exercise price and required withholding taxes, and separately describe 117 dividend equivalents credited to unvested restricted stock units under Amgen's equity incentive plan.
Amgen Inc. executive Nancy A. Grygiel, SVP & CCO, exercised nonqualified stock options for 1,970 and 1,000 shares of common stock on August 6, 2026, at exercise prices of $177.46 and $177.31 per share, respectively. She then sold 2,970 shares of common stock at $402.1601 per share in reported market transactions. According to the disclosure, the sales included shares used to cover the option exercise price and required withholding taxes related to expiring options. Following these transactions, 106.9449 shares are held indirectly through the company’s 401(k) Plan, and a portion of her reported holdings includes 68 Dividend Equivalents credited to unvested Restricted Stock Units.
MILES AMY E reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Amy E. Miles received an equity award of 665 shares of common stock as a grant under the company’s director incentive program. The award, structured as Restricted Stock Units that vested immediately and settle one-for-one in common shares, increased her direct holdings to 5,640 shares. This total includes 408 dividend equivalents credited to her unvested RSUs under a qualifying dividend reinvestment plan.
Kullman Ellen Jamison reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Ellen Jamison Kullman received a grant of 665 shares of common stock as a stock-based award. The award was in the form of Restricted Stock Units (RSUs) under Amgen’s 2009 director incentive and equity incentive plans and vested immediately, with each vested RSU paid in one share of common stock rather than through an open-market purchase.
After this grant, Kullman directly holds a total of 14,535.9807 Amgen shares, which include 2,121 dividend equivalents (DEs) that are credited to her unvested RSUs and will be paid in shares as those RSUs vest, along with cash for any remaining fractional share amount.
Klotman Mary E. reported acquisition or exercise transactions in this Form 4 filing.
Amgen director Mary E. Klotman received an equity award of 665 shares of common stock in the form of Restricted Stock Units. The RSUs were granted under Amgen’s 2009 Director Incentive Program and vested immediately, paying out in common shares on a one-to-one basis.
Following this grant, Klotman directly holds 2,211 shares of Amgen common stock, which include 18 dividend-equivalent units credited to her unvested RSUs under the company’s equity incentive plan.
Jacks Tyler reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Tyler Jacks reported a compensation-related equity grant rather than an open-market trade. He received 665 shares of common stock via immediately vesting Restricted Stock Units under Amgen’s 2009 Director Incentive Program. After this award, he directly holds 18,284 common shares, including 2,975 dividend equivalents tied to unvested RSUs that will be paid in stock as they vest.
ISHRAK OMAR reported acquisition or exercise transactions in this Form 4 filing.
Amgen director Omar Ishrak received a stock grant of 665 shares of common stock as compensation. The award was made as Restricted Stock Units under Amgen’s 2009 director incentive program and vested immediately, with payment in common shares on a one-to-one basis.
After this grant, Ishrak directly holds a total of 7,358.7361 Amgen common shares. Footnotes indicate the total includes 418 dividend equivalents credited to his unvested RSUs, which will also be settled in shares according to their vesting schedule.
Amgen Inc. director Charles M. Holley reported an equity award of 665 shares of common stock, received as a grant of Restricted Stock Units (RSUs) that vested immediately at no cash cost. The RSUs were granted under Amgen’s director incentive program and are settled one-for-one in common shares. Following this grant, Holley holds 12,799.0331 shares directly and an additional 1,260 shares indirectly through the Holley Family Trust. The direct holdings include 1,564 dividend equivalent (DE) units credited on unvested RSUs, which will convert into common shares as those RSUs vest.
Garland Greg C. reported acquisition or exercise transactions in this Form 4 filing.
AMGEN INC director Greg C. Garland received 665 shares of common stock through a stock award. The award was a grant of Restricted Stock Units under Amgen’s director incentive program, which vested immediately and was settled in shares on a one-to-one basis. Following this grant, Garland directly holds 13,848 shares of Amgen common stock.
Amgen Inc. director Robert Eckert received an equity award of 665 shares of common stock on May 19, 2026, reported as a grant or other acquisition at no purchase price. The award came from vested Restricted Stock Units under Amgen’s 2009 director incentive programs and vested immediately.
After this grant, Eckert directly holds 26,251 shares of Amgen common stock. This total includes 3,943 dividend equivalents (DEs) credited to his unvested RSUs under a dividend reinvestment plan, which will pay out in shares as those RSUs vest.
Druker Brian reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Brian Druker received an equity award of 665 shares of Amgen common stock as a grant under the company’s director incentive program. The award was in the form of Restricted Stock Units (RSUs) that vested immediately and are paid in common shares on a one-to-one basis.
Following this grant, Druker directly holds 8,391 shares of Amgen common stock, which include 408 dividend equivalents (DEs) credited to his unvested RSUs under a qualifying dividend reinvestment plan.
Drake Michael V reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Michael V. Drake received 665 shares of common stock as a grant of Restricted Stock Units (RSUs). The RSUs were awarded under Amgen’s 2009 Director Incentive Program and vested immediately, paying out in common shares on a one-to-one basis. Following this award, Drake directly holds about 5,774.2869 Amgen shares, including 339 dividend equivalents credited to his unvested RSUs.
Amgen Inc. director Wanda M. Austin received a stock-based compensation award. She acquired 665 shares of Amgen common stock on May 19, 2026 through a grant classified as a “grant, award, or other acquisition,” not an open-market purchase.
The shares came from Restricted Stock Units granted under Amgen’s 2009 Director Incentive Program within the company’s equity incentive plan. According to the footnote, these RSUs vested immediately and are paid in common stock on a one-to-one basis, with an option for the director to defer receipt. Following this grant, Austin directly holds 8,018 shares of Amgen common stock.
Amgen VP, Finance & CAO Matthew C. Busch reported a small tax-related share disposition. On the transaction date, 41 shares of Amgen common stock were withheld at $331.11 per share to cover tax obligations related to equity compensation. After this non-market tax-withholding event, Busch directly held 4,344 Amgen shares, which include 39 Dividend Equivalents tied to unvested Restricted Stock Units under the company’s equity incentive plan.
Amgen Inc. executive Esteban Santos reported routine share updates related to compensation and plan holdings. On May 7, 2026, 522 shares of Amgen common stock were disposed of in a tax-withholding transaction at $331.11 per share to satisfy exercise price or tax liabilities. After this, he directly owned 82,847 common shares. He also reported 909.9906 shares held indirectly through a 401K Plan. The reported holdings include 327 Dividend Equivalents credited to unvested Restricted Stock Units, which will be paid in common shares on a one-to-one basis according to their vesting schedule.
Amgen Inc. executive David M. Reese reported a routine tax-related share disposition. On 2026-05-07, 556 shares of Amgen common stock were withheld at $331.11 per share to satisfy tax obligations associated with equity compensation. After this withholding, he directly holds 42,256 shares of Amgen common stock. A footnote also notes 350 Dividend Equivalents tied to unvested Restricted Stock Units that will pay out in shares as they vest.
Amgen Inc. senior vice president of human resources Derek Miller reported a small tax-related share disposition. On May 7, 2026, 151 shares of Amgen common stock were withheld at $331.11 per share to cover tax obligations, a non-market transaction. After this event, Miller directly holds 12,444 shares, which include 99 dividend equivalents tied to unvested restricted stock units that will settle in shares as they vest.
Amgen Inc. senior vice president Rachna Khosla had 93 shares of common stock withheld on May 7, 2026 to cover tax obligations. The shares were valued at $331.11 each. After this tax-withholding disposition, she directly holds 8,394 shares of Amgen common stock.
Amgen Inc. senior vice president and chief compliance officer Nancy A. Grygiel reported routine share activity involving Amgen common stock. The filing shows a tax-withholding disposition of 88 shares of common stock at $331.11 per share, used to cover tax obligations rather than representing an open-market sale. After this transaction, she holds 7,330 Amgen shares directly. The filing also notes an indirect holding of 106.1864 shares in a 401(k) plan, which includes 58 Dividend Equivalents tied to unvested Restricted Stock Units that will be paid out in shares as they vest.
Amgen Inc. executive Peter H. Griffith, EVP & CFO, reported a routine tax-related share disposition. On the reported date, 556 shares of Amgen common stock were surrendered at $331.11 per share to cover tax obligations, a non-market "tax-withholding disposition" rather than an open-market sale.
Following this transaction, Griffith directly held 50,150 shares of Amgen common stock. A footnote explains that his holdings include Dividend Equivalents credited to unvested Restricted Stock Units under Amgen’s equity incentive plan, which are paid in shares as those awards vest.
Amgen Inc. executive Jonathan P. Graham reported a small tax-related share disposition. On the transaction date, 499 shares of Amgen common stock were withheld at $331.11 per share to cover exercise price or tax liability, a routine administrative event rather than an open-market sale.
After this tax-withholding disposition, Graham directly held 39,712 Amgen shares. His holdings include 311 Dividend Equivalents granted under Amgen’s equity incentive plan, which are tied to unvested Restricted Stock Units and pay out in shares on a one-to-one basis as those awards vest.
Amgen Inc. executive vice president of Global Commercial Operations Murdo Gordon reported a small stock transaction related to taxes. On a Form 4, he showed a tax-withholding disposition of 615 shares of Amgen common stock at $331.11 per share, a mechanistic step to cover obligations associated with equity compensation rather than an open-market sale. After this transaction, he directly holds 51,222 shares of Amgen common stock. The reported holdings include 386 Dividend Equivalents tied to unvested restricted stock units under Amgen’s equity incentive plan, which will be paid out in shares as those units vest.
Amgen Inc. Chairman, CEO and President Robert A. Bradway reported a routine tax-withholding transaction in company stock. On 2026-05-07, 2,079 shares of Amgen common stock were withheld at $331.11 per share to satisfy tax obligations, not as an open-market sale.
Following this withholding, Bradway directly owns 505,160 shares of Amgen common stock. He also reports indirect holdings through related parties, including shares held by his spouse and in spousal GRAT and GRAT vehicles, reflecting additional indirect economic exposure to Amgen stock.
Amgen Inc. EVP of Research and Development James E. Bradner reported a small tax-related share disposition. On the reported date, 446 shares of common stock were withheld at $331.11 per share to satisfy tax obligations, a non-market transaction classified as a tax-withholding disposition.
After this event, Bradner directly held 30,016 Amgen shares. The reported holdings include 1,273 dividend equivalents tied to unvested restricted stock units that will pay out in Amgen common stock as they vest, along with cash for any fractional share amounts.
Amgen Inc. executive James E. Bradner reported routine equity compensation activity. On May 5, 2026, he acquired 3,337 Restricted Stock Units (RSUs) at $0.00 per share, which vest in four equal annual installments of 25% each starting on May 5, 2027. These shares include 1,332 Dividend Equivalents (DEs) that will be paid in common stock following the same vesting schedule. He was also granted 21,773 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from May 5, 2027 and expiring on May 5, 2036. On May 6, 2026, 407 shares of common stock were disposed of at $329.59 per share to cover tax obligations, a non-market tax-withholding disposition. After these transactions, Bradner directly holds 30,462 shares of Amgen common stock.
Amgen Inc. Chairman, CEO and President Robert A. Bradway reported routine equity compensation and related tax withholding. On May 5, 2026, he received 12,136 Restricted Stock Units (RSUs) at $0.00 per share and 79,176 non-qualified stock options with a $329.59 exercise price, all granted under Amgen’s Equity Incentive Plan.
The RSUs and options each vest in four equal annual installments of 25% starting on May 5, 2027, with vested RSUs settled in common shares and the options exercisable through May 5, 2036. A separate F-code transaction on May 6, 2026 reflects 1,702 shares used to satisfy tax obligations at $329.59 per share, not an open-market sale. After these transactions, Bradway directly holds 507,239 common shares, in addition to indirect holdings by his spouse and related GRATs.
Amgen executive Matthew C. Busch, VP Finance & CAO, reported routine equity compensation grants and related tax withholding. He received 455 shares of common stock as Restricted Stock Units, including 45 Dividend Equivalents, under Amgen’s Equity Incentive Plan. These RSUs vest in four equal 25% installments starting on 5/5/2027 and are settled in common shares.
Busch also received 2,969 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from 5/5/2027 until expiration on 5/5/2036. To cover tax obligations, 50 shares of common stock were disposed of at $329.59 per share as a tax-withholding transaction, not an open-market sale. After these transactions, he directly holds 4,385 common shares.
Amgen EVP Murdo Gordon reported new equity awards and a small tax-related share withholding. On May 5, 2026, he received 3,640 Restricted Stock Units (RSUs) that vest in four equal annual installments of 25% starting on May 5, 2027, and will be settled in common shares. These RSUs include 458 Dividend Equivalents credited under Amgen’s Equity Incentive Plan. He was also granted 23,752 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from May 5, 2027, and expiring on May 5, 2036. On May 6, 2026, 502 shares of common stock were disposed of at $329.59 per share to satisfy tax obligations, a non-market "F" code withholding. After these transactions, Gordon directly holds 51,837 Amgen common shares.
Amgen Inc. executive vice president and general counsel Jonathan P. Graham reported routine equity compensation changes. On May 5, 2026, he received 2,609 shares of common stock at no cost as a grant, increasing his direct holdings to 40,619 shares. The same day, he was granted 17,022 non-qualified stock options with an exercise price of $329.59 per share, exercisable in four equal annual installments starting May 5, 2027 and expiring in 2036. These options relate to an equal number of underlying common shares. On May 6, 2026, 408 shares were disposed of at $329.59 per share to satisfy tax obligations, leaving him with 40,211 shares held directly. The restricted stock units and options vest in four annual installments of 25% each beginning in 2027, and vested RSUs and related dividend equivalents will be settled in common shares on a one-to-one basis.
Amgen EVP & CFO Peter H. Griffith reported routine equity compensation and related tax withholding. On May 5, 2026, he received 3,640 shares of Common Stock as a grant valued at $0.0000 per share, tied to Restricted Stock Units under Amgen’s Equity Incentive Plan. These RSUs, including 424 Dividend Equivalents, vest in four equal 25% installments starting on May 5, 2027 and will be settled in common shares.
He was also granted 23,752 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from May 5, 2027 and expiring on May 5, 2036. On May 6, 2026, 502 shares of Common Stock were disposed of at $329.59 per share to cover tax obligations. After these transactions, he directly holds 50,706 shares of Amgen common stock.
Amgen SVP & CCO Nancy A. Grygiel reported routine equity compensation activity. She received 485 shares of common stock as a grant, increasing her direct holdings to 7,494 shares, and was granted 3,167 non-qualified stock options at $329.59 per share, vesting in four annual installments starting on May 5, 2027.
The filing also shows 76 shares were withheld at $329.59 per share to cover tax obligations, leaving 7,418 directly held shares afterward. The stock grant consists of Restricted Stock Units that convert one-for-one into common shares as they vest, and the options are exercisable in equal parts through May 5, 2030 with an expiration on May 5, 2036. An indirect 401(k) holding of 106.1864 shares is also reported.
Amgen Inc. senior vice president Rachna Khosla reported routine equity compensation changes. On May 5, 2026, she received an award of 500 shares of common stock at $0.00 per share and a grant of 3,266 non-qualified stock options with a $329.59 exercise price, all under Amgen’s Equity Incentive Plan. The options and related Restricted Stock Units vest in four equal annual installments of 25% each, beginning on May 5, 2027. On May 6, 2026, 79 shares of common stock at $329.59 were withheld to cover tax obligations. After these transactions, she directly holds 8,487 shares of Amgen common stock.
Amgen Inc. senior vice president of human resources Derek Miller reported routine equity compensation activity. He received 910 shares of common stock as a grant, which the footnotes describe as Restricted Stock Units that vest in four equal annual installments of 25% starting on May 5, 2027, and include 116 Dividend Equivalents credited under Amgen’s equity incentive plan.
He was also granted 5,938 non-qualified stock options with an exercise price of $329.59 per share, vesting 25% per year from May 5, 2027 until expiration on May 5, 2036. Separately, 123 shares of common stock were disposed of at $329.59 per share to cover tax obligations, a non-market tax-withholding transaction. After these transactions, Miller directly holds 12,595 Amgen shares.
Amgen Inc. executive David M. Reese reported routine equity compensation awards and a small tax-related share disposition. He received 2,912 shares of Common Stock as a grant on May 5, 2026, including 415 Dividend Equivalents, under Amgen’s Equity Incentive Plan. These Restricted Stock Units vest in four equal annual installments of 25% starting on May 5, 2027, with proration based on completed months of active employment in 2026, and will be settled in common shares on a one-to-one basis. He was also granted 19,002 non-qualified stock options at an exercise price of $329.59 per share, vesting in four equal annual installments of 25% beginning on May 5, 2027 and expiring on May 5, 2036. On May 6, 2026, 454 shares of Common Stock were disposed of at $329.59 per share to cover tax obligations, leaving him with 42,812 Common shares held directly.
Amgen executive Esteban Santos reported routine equity compensation and a small tax-related share disposition. He received 2,730 shares of Amgen common stock on May 5, 2026 as a grant under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. These Restricted Stock Units vest in four equal annual installments of 25% each, beginning on May 5, 2027, and will be settled one-for-one in common shares as they vest.
On the same date, he was granted non-qualified stock options covering 17,814 shares of common stock at $329.59 per share, also vesting in four annual 25% installments starting on May 5, 2027 and expiring on May 5, 2036. On May 6, 2026, 427 shares of common stock valued at $329.59 per share were withheld to cover tax obligations, leaving him with 83,369 directly held shares. He also has 909.9906 shares held indirectly through a 401K plan.
ISHRAK OMAR reported acquisition or exercise transactions in this Form 4 filing.
Amgen director Omar Ishrak reported an equity award of 106.1925 shares of Common Stock on a grant/award basis, not an open-market purchase. Following this award, his direct holdings total 6,693.7361 shares of Amgen common stock.
The total includes 418 Dividend Equivalents (DEs) credited under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. These DEs are linked to unvested Restricted Stock Units and will be paid out in shares on a one-to-one basis as those units vest.
HOLLEY CHARLES M reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Charles M. Holley reported updated equity holdings. On May 5, 2026, he received a grant or award of 128.9481 shares of Amgen common stock at no cash cost, increasing his direct ownership to 12,134.0331 shares.
He also reports indirect ownership of 1,260 shares through the Holley Family Trust. The reported holdings include 1,564 Dividend Equivalents credited to his unvested Restricted Stock Units, which are payable in Amgen common stock on a one-for-one basis as those units vest.
Drake Michael V reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Michael V. Drake received a stock award of 79.6444 shares of common stock on May 5. The grant was recorded at no per-share price, indicating compensation rather than an open-market purchase. After this award, his direct holdings total 5109.2869 shares.
The holdings figure includes 339 Dividend Equivalents granted under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan. These Dividend Equivalents are tied to unvested Restricted Stock Units and will be paid out in common shares on a one-to-one basis as the units vest.
Amgen Inc. executive Esteban Santos, EVP of Operations, reported compensation-related share activity in Common Stock. On May 2, 2026, he had 1,338 shares withheld as a tax-withholding disposition in two F-code transactions at $329.82 per share, a non‑market mechanism used to satisfy tax obligations on equity awards rather than an open-market sale. He also reported 909.9906 shares held indirectly through the Company’s 401(k) Plan, representing interests in Amgen’s stock fund.
Amgen Inc. executive David M. Reese reported routine tax-related share dispositions. On May 2, 2026, a total of 1,433 shares of Amgen common stock were withheld at $329.82 per share to cover tax obligations, classified as tax-withholding dispositions rather than open-market sales.
A footnote notes that the reported holdings include 442 Dividend Equivalents tied to unvested Restricted Stock Units, which will be paid in common shares on a one-to-one basis as those units vest.
Amgen Inc. senior vice president of human resources Derek Miller reported routine share dispositions tied to tax withholding, not open-market sales. On May 2, 2026, a total of 365 shares of Amgen common stock were withheld at $329.82 per share to cover tax liabilities on equity awards.
A footnote explains that his holdings include 123 Dividend Equivalents credited under Amgen’s equity incentive plan, which will be paid out as common shares on a one-for-one basis as related restricted stock units vest.
Amgen Inc. SVP Rachna Khosla reported routine tax-withholding share dispositions. On May 2, 2026, a total of 225 shares of Amgen common stock were withheld at $329.82 per share to cover tax liabilities tied to equity awards, not as open-market sales. She continues to hold a direct stake in Amgen stock, and her holdings also reflect 73 dividend equivalents linked to unvested restricted stock units that will settle in shares as they vest.
Amgen Inc. senior vice president and chief compliance officer Nancy A. Grygiel reported multiple transactions in the company’s common stock. On May 4, 2026, she completed an open-market sale of 1,237 shares at an average price of $323.7272 per share. On May 2, 2026, two F-code tax-withholding dispositions of 116 and 126 shares at $329.82 per share were recorded to cover tax obligations. After these transactions, she directly holds 7,009 shares of Amgen common stock and has an additional 106.1864 shares indirectly through the company’s 401(k) Plan. Her holdings also reflect 72 Dividend Equivalents tied to unvested restricted stock units that pay out in shares as they vest.
Amgen Inc. EVP & CFO Peter H. Griffith reported two tax-related share dispositions of company common stock. On May 2, 2026, he delivered 687 shares and 746 shares of Amgen stock at $329.82 per share each as tax-withholding transactions, not open-market sales.
After these dispositions, his reported direct holdings in Amgen common stock were 47,568 shares following one transaction and 48,255 shares following the other. A footnote notes that his holdings include 454 Dividend Equivalents tied to unvested Restricted Stock Units under Amgen’s equity incentive plan, which pay out in shares as the awards vest.
Amgen Inc. executive vice president and general counsel Jonathan P. Graham reported two routine tax-related share dispositions. On May 2, 2026, a total of 1,257 shares of Amgen common stock were withheld at $329.82 per share to satisfy tax obligations on equity awards, rather than sold on the open market. Following these transactions, his reported direct holdings in the affected accounts were 38,010 and 38,620 shares of common stock.